RBC Capital analyst Brian Abrahams maintained a Buy rating on 89bio (ETNB – Research Report) on January 13 and set a price target of $27.00. The company’s shares closed last Friday at $10.50.
Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, Biogen, and Incyte. According to TipRanks, Abrahams has an average return of 7.7% and a 49.30% success rate on recommended stocks.
89bio has an analyst consensus of Strong Buy, with a price target consensus of $26.20.
See Insiders’ Hot Stocks on TipRanks >>
ETNB market cap is currently $488.6M and has a P/E ratio of -2.41.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ETNB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Read More on ETNB:
- 89bio Provides Business Update and Outlook for 2023
- Trial success is rocketing this NASH stock higher and sinking these peers
- 89bio should be bought on Madrigal data selloff, says RBC Capital
- 89bio announces publication of Phase 1b/2a pegozafermin study results
- 89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
